Hala N ElShagea

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 6

Top Topics

Low Density Lipoprotein

Hyaluronic Acid

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Ahmed M Agiba, Nihal Elsayyad, Hala N ElShagea, Mahmoud A Metwalli, Amin Orash Mahmoudsalehi, Saeed Beigi-Boroujeni, Omar Lozano, Alan Aguirre-Soto, Jose Luis Arreola-Ramirez, Patricia Segura-Medina, Raghda Rabe Hamed
Advances in Light-Responsive Smart Multifunctional Nanofibers: Implications for Targeted Drug Delivery and Cancer Therapy. Pharmaceutics 16 (8) (2024)
Ahmed M Agiba, Nihal Elsayyad, Hala N ElShagea, Mahmoud A Metwalli, Amin Orash Mahmoudsalehi, Saeed Beigi-Boroujeni, Omar Lozano, Alan Aguirre-Soto, Jose Luis Arreola-Ramirez, Patricia Segura-Medina, Raghda Rabe Hamed
Advances in Light-Responsive Smart Multifunctional Nanofibers: Implications for Targeted Drug Delivery and Cancer Therapy. Pharmaceutics 16 (8) (2024)
Hala N ElShagea, Rana R Makar, Alaa H Salama, Nermeen A Elkasabgy, Emad B Basalious
Investigating the Targeting Power to Brain Tissues of Intranasal Rasagiline Mesylate-Loaded Transferosomal In Situ Gel for Efficient Treatment of Parkinson's Disease. Pharmaceutics 15 (2) (2023)
Hala N ElShagea, Rana R Makar, Alaa H Salama, Nermeen A Elkasabgy, Emad B Basalious
Investigating the Targeting Power to Brain Tissues of Intranasal Rasagiline Mesylate-Loaded Transferosomal In Situ Gel for Efficient Treatment of Parkinson's Disease. Pharmaceutics 15 (2) (2023)
Hala N ElShagea, Rana R Makar, Alaa H Salama, Nermeen A Elkasabgy, Emad B Basalious
Investigating the Targeting Power to Brain Tissues of Intranasal Rasagiline Mesylate-Loaded Transferosomal In Situ Gel for Efficient Treatment of Parkinson's Disease. Pharmaceutics 15 (2) (2023)
Hala N ElShagea, Rana R Makar, Alaa H Salama, Nermeen A Elkasabgy, Emad B Basalious
Investigating the Targeting Power to Brain Tissues of Intranasal Rasagiline Mesylate-Loaded Transferosomal In Situ Gel for Efficient Treatment of Parkinson's Disease. Pharmaceutics 15 (2) (2023)